Scotiabank initiated coverage of Blueprint Medicines (BPMC) with an Outperform rating and $150 price target Stock performance has been “choppy,” but greater appreciation of the company’s $4B ...
Scotiabank started coverage on shares of Blueprint Medicines (NASDAQ:BPMC – Free Report) in a report issued on Friday, Marketbeat Ratings reports. The firm issued a sector outperform rating and ...
Fintel reports that on March 7, 2025, Scotiabank initiated coverage of Blueprint Medicines (LSE:0HOJ) with a Sector Outperform recommendation. As of March 4, 2025, the average one-year price ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback